HomeCompareJWTXF vs ABBV

JWTXF vs ABBV: Dividend Comparison 2026

JWTXF yields 4.14% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JWTXF wins by $1.01M in total portfolio value· pulled ahead in Year 3
10 years
JWTXF
JWTXF
● Live price
4.14%
Share price
$7.50
Annual div
$0.31
5Y div CAGR
56.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.11M
Annual income
$728,998.92
Full JWTXF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JWTXF vs ABBV

📍 JWTXF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJWTXFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JWTXF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JWTXF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JWTXF
Annual income on $10K today (after 15% tax)
$351.59/yr
After 10yr DRIP, annual income (after tax)
$619,649.08/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, JWTXF beats the other by $598,593.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JWTXF + ABBV for your $10,000?

JWTXF: 50%ABBV: 50%
100% ABBV50/50100% JWTXF
Portfolio after 10yr
$607.4K
Annual income
$376,885.34/yr
Blended yield
62.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JWTXF
No analyst data
Altman Z
2.9
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JWTXF buys
0
ABBV buys
0
No recent congressional trades found for JWTXF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJWTXFABBV
Forward yield4.14%3.06%
Annual dividend / share$0.31$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR56.9%40.6%
Portfolio after 10y$1.11M$102.3K
Annual income after 10y$728,998.92$24,771.77
Total dividends collected$1.05M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JWTXF vs ABBV ($10,000, DRIP)

YearJWTXF PortfolioJWTXF Income/yrABBV PortfolioABBV Income/yrGap
1$11,349$649.00$11,550$430.00$201.00ABBV
2$13,223$1,080.05$13,472$627.96$249.00ABBV
3← crossover$15,994$1,845.31$15,906$926.08+$88.00JWTXF
4$20,387$3,272.89$19,071$1,382.55+$1.3KJWTXF
5$27,931$6,117.22$23,302$2,095.81+$4.6KJWTXF
6$42,176$12,289.42$29,150$3,237.93+$13.0KJWTXF
7$72,339$27,210.99$37,536$5,121.41+$34.8KJWTXF
8$145,840$68,437.32$50,079$8,338.38+$95.8KJWTXF
9$358,368$202,318.73$69,753$14,065.80+$288.6KJWTXF
10$1,112,452$728,998.92$102,337$24,771.77+$1.01MJWTXF

JWTXF vs ABBV: Complete Analysis 2026

JWTXFStock

The Japan Wool Textile Co., Ltd. operates in the textile industry in Japan. It operates through four business lines: Textile & Clothing Materials, Industrial Machinery & Materials, Human & Future Development, and Consumer Goods & Services. The Textile & Clothing Materials business manufactures and sells knitting wool for fabric/knitting, uniform-related materials and products, and men's and women's fashion materials. The Industrial Machinery & Materials business is involved in the development, manufacture, and sale of various materials, including wool, chemical synthetic fibers, and threads through twine/felt/non-woven fabrics. It also designs, manufactures, and sells industrial machinery; and designs, installs, and maintains environmental/energy systems. The Human & Future Development business provides daycare, childcare/after-school care, small group home care, welfare equipment rental and sales, and house renovations services, as well as engages in the commercial facility operation, Children's amusement facility, ice cream, video rental, snack sales, and cellular phone businesses. It also operates tennis schools, golf courses, driving ranges, and equestrian clubs, as well as Karaoke and bowling alleys; rental of office buildings; provision of rental office management services; and sale of residential land and construction of houses. The Consumer Goods & Services business provides ballroom dance attires, office and industrial use inks, clothing, horse gear and other equestrian products, and stamps and stamp-related products and services; and insurance agency and logistics services, as well as offers beds and bedding, furniture, and other related goods online. The company was incorporated in 1896 and is headquartered in Osaka, Japan.

Full JWTXF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JWTXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JWTXF vs SCHDJWTXF vs JEPIJWTXF vs OJWTXF vs KOJWTXF vs MAINJWTXF vs JNJJWTXF vs MRKJWTXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.